Michael D. Farwell - Concepedia

Author

Michael D. Farwell

Also Known As

M. Farwell, M.D. Farwell, Mary F. Farwell, Michael D Farwell, Michael D. Farwell, Michael Farwell, Micheal D. Farwell, Tina J Hieken

104

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Children's Hospital of Philadelphia Parker Institute for Cancer Immunotherapy Abramson Cancer Center Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Michael D. Farwell is an author at University of Pennsylvania specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.4K
2	Immunology	7	7	616
3	Cell Biology	5	5	155
4	Health Sciences	2	2	725
5	Engineering	1	1	17

Michael D. Farwell

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma Alexander C. Huang, Robert Orlowski, Xiaowei Xu, Nature Medicine Neoadjuvant Pd-1 BlockadeSurgical OncologyMedicineMelanomaSingle Dose	2019	683
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial Vivek Narayan, Julie S. Barber-Rotenberg, In-Young Jung, Nature Medicine UrologyCancer ImmunosurveillanceGenitourinary CancerMedicineImmunology	2022	455
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting Neeta Pandit‐Taskar, Michael A. Postow, Matthew D. Hellmann, Journal of Nuclear Medicine	2019	249
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer Mehran Makvandi, Austin R. Pantel, Lauren E. Schwartz, Journal of Clinical Investigation	2018	131
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Journal of Nuclear Medicine	2021	113
Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene Mark A. Sellmyer, Sarah A. Richman, Katheryn Lohith, Molecular Therapy	2019	107
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours Amit Maity, Rosemarie Mick, Alexander C. Huang, British Journal of Cancer	2018	101
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells Kevin Wang, Paulina Coutifaris, David Brocks, Cancer Cell Cancer ImmunosurveillanceAutoimmune DiseaseT-regulatory CellImmunologyAutoimmunity	2024	73
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74 Iris K. Lee, Estela Noguera-Ortega, Zebin Xiao, Clinical Cancer Research	2022	44
Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer Elizabeth S. McDonald, Robert K. Doot, Austin R. Pantel, JAMA Oncology Breast OncologyOncologic ImagingPathologyPositron Emission TomographyOncology	2020	42

Page 1